AKT, EGFR, C-ErbB-2, and C-Kit Expression in Uterine Carcinosarcoma
AKT, EGFR, C-ErbB-2, and C-Kit Expression in Uterine Carcinosarcoma
复制标题
AKT、EGFR、C-ErbB-2 和 C-Kit 在子宫癌肉瘤中的表达
DOI：
--
复制
发表时间：
2013
影响因子：
2.4
通讯作者：
G. Toruner
中科院分区：
文献类型：
--
作者：
O. Saglam;Seema Husain;G. Toruner
子宫癌肉瘤（UCS）占美国子宫癌相关死亡的约15%。由于缺乏有效的治疗方式，识别潜在的分子缺陷可能允许引入靶向治疗。采用免疫组织化学方法检测37例UCS（包括23例早期（I和II）和14例晚期（III和IV）肿瘤）中AKT、上皮生长因子受体、C-Kit和C-ErbB-2的表达，并对PIK 3CA基因第9和第20外显子进行测序。23个（62%）的UCS是同源的;其余的包含异源元素。纯浆液性癌13例（35%），类浆液性癌12例（32%）。计算AKT、上皮生长因子受体和C-Kit的免疫染色评分，范围为0至（6+）。根据美国临床肿瘤学会/美国病理学家学会标准对C-ErbB-2染色进行评分。AKT染色见于35/37例，免疫染色评分范围为（2+）至（5+）。AKT在早期乳腺癌中的表达明显高于晚期乳腺癌（P=0.016）。上皮成分中AKT的表达与生存率相关（P=0.026）。37例中21例上皮生长因子受体阳性。仅8例C-Kit免疫组化评分为≥ 3+。C-ErbB-2免疫组化3+ 1例。在1例癌性和肉瘤性组织中均检测到PIK 3CA基因H1047 R突变。这些结果表明，AKT通路可能是重要的UCS的发病机制。有必要进行更大队列的进一步研究，以证实本研究中观察到的相关性。
Uterine carcinosarcoma (UCS) accounts for approximately 15% of uterine cancer-associated deaths in the United States. With lack of effective treatment modalities, identification of underlying molecular defects may allow the introduction of targeted treatments. The expression of AKT, epithelial growth factor receptor, C-Kit, and C-ErbB-2 were studied by immunohistochemistry and exons 9 and 20 of PIK3CA gene were sequences in a cohort of 37 UCS, including 23 early-stage (I and II) and 14 late-stage (III and IV) tumors. Twenty-three (62%) of the UCS were homologous; the reminder contained heterologous elements. The carcinomatous component was pure serous carcinoma in 13 (35%), endometrioid in 12 (32%) cases. An immunostaining score ranging from 0 to (6+) was calculated for AKT, epithelial growth factor receptor, and C-Kit. C-ErbB-2 staining was scored by American Society of Clinical Oncology/College of American Pathologists criteria. AKT staining was seen in 35/37 cases with an immunostaining score ranging from (2+) to (5+). AKT was expressed significantly more in the early-stage than late-stage disease (P=0.016). The expression of AKT in the epithelial component was associated with the survival (P=0.026). Epithelial growth factor receptor was positive in 21/37 cases. Only 8 cases showed (⩽3+) immunostaining score with C-Kit. C-ErbB-2 immunostain was (3+) in only 1 case. An H1047R mutation on PIK3CA gene was detected in both carcinomatous and sarcomatous components in a single case. These results indicate that AKT pathway may be important in pathogenesis of UCS. Further studies with larger cohorts are warranted to confirm the observed associations in this study.
影响因子：
11.2
作者：
Hutchinson, JN;Jin, J;Muller, WJ
通讯作者：
Muller, WJ